Redox Bioscience Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Redox Bioscience General Information

Description

Developer of thioredoxin based drugs designed to treat respiratory diseases. The company's drugs are used to cure stress associated disorders, enabling healthcare providers to treat the patients and improve their lives.

Contact Information

Website
www.rbs-i.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 6-2 Higashimarutacho Sakyo-ku
  • Kyoto-fu
  • Kyoto-shi, 606-8395
  • Japan
+81 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Redox Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Startup
To view Redox Bioscience’s complete valuation and funding history, request access »

Redox Bioscience Executive Team (3)

Name Title Board Seat Contact Info
Kiyoaki Yamauchi Co-President & Chief Executive Officer
Kenji Sugita Ph.D Co-President & Board Member
Junji Yodoi Co-Founder, Advisor & Chief Technical Officer
To view Redox Bioscience’s complete executive team members history, request access »

Redox Bioscience Board Members (10)

Name Representing Role Since
Kenji Sugita Ph.D Redox Bioscience Co-President & Board Member 000 0000
Kiyohara Yoshihiro Redox Bioscience Board Member 000 0000
Koichi Yamamoto Redox Bioscience Board Member 000 0000
Masao Kato Redox Bioscience Board Member 000 0000
Minoru Okuda Redox Bioscience Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Redox Bioscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioFrontier Partners Venture Capital Minority 000 0000 000000 0
To view Redox Bioscience’s complete investors history, request access »